Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been assigned an average recommendation of "Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $34.78.

XNCR has been the subject of several research reports. BMO Capital Markets reaffirmed an "outperform" rating and set a $32.00 price target on shares of Xencor in a research report on Tuesday, August 6th. Royal Bank of Canada increased their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a research report on Thursday, September 26th. Wedbush reiterated an "outperform" rating and set a $34.00 price target on shares of Xencor in a research note on Monday, September 9th. Finally, JPMorgan Chase & Co. reduced their price objective on Xencor from $30.00 to $27.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st.

Xencor Price Performance

Shares of NASDAQ XNCR remained flat at $21.16 during midday trading on Friday. 392,901 shares of the stock traded hands, compared to its average volume of 606,948. The firm's 50 day moving average is $19.51 and its 200 day moving average is $20.10. Xencor has a 52-week low of $15.31 and a 52-week high of $26.84. The company has a current ratio of 6.92, a quick ratio of 6.92 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.30 billion, a P/E ratio of -9.66 and a beta of 0.67.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The business had revenue of $16.96 million for the quarter, compared to analysts' expectations of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business's revenue for the quarter was down 62.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.37) earnings per share. As a group, analysts expect that Xencor will post -4.11 EPS for the current fiscal year.

Institutional Trading of Xencor

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Xencor by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 6,767,249 shares of the biopharmaceutical company's stock valued at $143,669,000 after buying an additional 115,886 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Xencor during the first quarter valued at $229,000. Diversified Trust Co increased its holdings in Xencor by 4.5% in the 1st quarter. Diversified Trust Co now owns 13,059 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 563 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Xencor by 10.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 33,942 shares of the biopharmaceutical company's stock worth $751,000 after purchasing an additional 3,144 shares in the last quarter. Finally, Texas Permanent School Fund Corp boosted its holdings in shares of Xencor by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company's stock valued at $1,179,000 after purchasing an additional 690 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.